Curanex Pharmaceuticals Inc Common Stock (CURX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -954.56K | -857.4K | -9.19M | -290.08K | -149.95K | -236.33K |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -536.59% | - | - | -22.75% | - | - |
| Net Income | -3.15M | -3.07M | -954.06K | -60.35K | -137.58K | -44.2K |
| Depreciation & Amortization | 35.04K | 34.29K | 15.44K | 15.03K | 14.63K | 0 |
| Stock-Based Compensation | 9.79K | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.15M | 2.18M | -8.52M | 0 | 0 | 0 |
| Working Capital Changes | 0 | 0 | 271.76K | -244.76K | -27K | -192.13K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 5.98K | -112.06K | 114.22K | -125.79K | 121.06K | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 0 | 14.91M | 200K | 200K | 580.1K |
| Debt Issued (Net) | 0 | -400K | 0 | 200K | 200K | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 630.1K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 400K | 14.91M | 0 | 0 | -50K |
| Net Change in Cash | -954.56K | -857.4K | 5.72M | -90.08K | 50.05K | 374.26K |
| Free Cash Flow | -954.56K | -857.4K | -9.19M | -290.08K | -149.95K | -236.33K |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -536.59% | - | - | -22.74% | - | - |
| FCF per Share | -0.03 | -0.03 | -0.36 | -0.01 | -0.01 | -0.01 |
| FCF Conversion (FCF/Net Income) | 0.30x | 0.28x | 9.63x | 4.81x | 1.09x | 5.35x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |